Ceretrophin Clinical Study
A double-blind, placebo controlled study examining the effects of Ceretrophin™ vs placebo on cognitive function, energy, state-of-mind and mood.
By Dr. Con Stough, Christina Kure, Jo Tarasuik and Luke Downey
BRAIN SCIENCES INSTITUTE SWINBURNE UNIVERSITY, AUSTRALIA Dr. Con Stough BSI Director
Examine whether Ceretrophin™ enhances performance on tests assessing memory, attention, executive function, alertness, speed of information processing, mood, energy levels, stress and IQ.
This study was a Phase III, double blind, placebo controlled exploratory trial with 150 healthy human participants that examined the neuropsychological effects of Ceretrophin™. It was expected that treatment with Ceretrophin™ would produce improvements in cognitive functioning, in particular memory, attention and executive processing. It was also anticipated that Ceretrophin™ would exert additional benefits in improving energy levels, anxiety, depression and stress.
The Cognitive Drug Research measure (CDR)
UWIST Mood Adjective Checklist
Spielberger State-Trait Anxiety Inventory
The General Health Questionnaire (GHQ)
IQ: Raven Progressive Matrices
Click Here to download the Ceretrophin™ Technical Report
Peer Review Publications
Archives of General Psychiatry
International Journal of Neuropsychopharmacology